Beneficial effects of pioglitazone on cholangiohepatitis induced by bile duct carcinoma

Intern Med. 2007;46(20):1723-7. doi: 10.2169/internalmedicine.46.0312. Epub 2007 Oct 15.

Abstract

Cholangiocarcinoma is a predominantly fatal cancer, which can be difficult to treat. We report a 73-year-old man who developed cholangiocarcinoma with cholangiohepatitis and diabetes. Administration of pioglitazone, peroxisome proliferator-activated receptor gamma (PPARgamma). agonist, improved not only diabetic control, but also the tumor-induced cholangiohepatitis, and improved the patient's quality of life. Although he finally died of obstructive jaundice, thiazolidinedione should be considered for treatment of tumor-induced hepatitis in the presence of diabetes, unless severe side effects occur.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Bile Duct Neoplasms / complications
  • Bile Duct Neoplasms / pathology*
  • Bile Ducts, Intrahepatic*
  • Cholangiocarcinoma / complications
  • Cholangiocarcinoma / pathology*
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Hepatitis / drug therapy
  • Hepatitis / etiology*
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Male
  • PPAR gamma / antagonists & inhibitors*
  • Pioglitazone
  • Thiazolidinediones / therapeutic use*

Substances

  • Hypoglycemic Agents
  • PPAR gamma
  • Thiazolidinediones
  • Pioglitazone